Co-Diagnostics, Inc. CEO to Present at 2017 SALSS
August 22 2017 - 7:30AM
Business Wire
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or
the “Company”), a molecular diagnostics company with a unique,
proprietary platform for the development of diagnostic tests,
announced today that CEO Dwight Egan will be a presenter at the
2017 Swedish-American Life Science Summit (SALSS), taking place
August 23-25 in Stockholm, Sweden.
The SALSS began in 2005 as an invitation-only platform to
increase international business and cooperation between the United
States and Sweden, one of the most important life science industry
centers in Europe. Activities include high-level panel discussions,
insights from keynote speakers and presentations from distinguished
life science executives and investors throughout the world. Mr.
Egan, who last attended SALSS in 2015, will again be presenting
along with many of these individuals, with a focus this year on the
Cancer Moonshot, health technology transformation, and impact
investing.
Mr. Egan commented: “We look forward to becoming reacquainted
with so many prominent leaders in both the world of biotechnology
and in the investment community, and to update them on the
potential of our unique CoPrimer™ technology to contribute to the
science of liquid biopsies, companion diagnostics, and multiplex
cancer screenings. Following our recent IPO, we are positioned to
make the most of these relationships to facilitate global
application of our technology and approach to high-quality,
low-cost diagnostic solutions.”
About Co-Diagnostics, Inc.:Co-Diagnostics, Inc., a Utah
corporation, is a molecular diagnostics company that has developed
and intends to manufacture and sell reagents used for diagnostic
tests that function via the detection and/or analysis of nucleic
acid molecules (DNA or RNA), and to sell diagnostic equipment from
other manufacturers as self-contained lab systems.
Forward-Looking Statements:This press release contains
forward-looking statements. Forward-looking statements can be
identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions. Readers
of this press release are cautioned not to place undue reliance on
any forward-looking statements. The Company does not undertake any
obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
Disclaimer:This news release does not constitute an offer
to sell or a solicitation of an offer to buy the securities
described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170822005558/en/
Co-DiagnosticsInvestor Relations,
801-438-1036investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024